logo-loader
viewEXMceuticals

EXMceuticals secures supply and offtake agreements-in-principle for proposed Portugal refinery

The company has also signed an outline letter of intent with one counterparty for the offtake of the eventual supply of finished pharmaceutical and medical grade cannabis ingredients

EXMceuticals - EXMceuticals secures supply and offtake agreements-in-principle for proposed Portugal refinery
EXM also said Farmceutica Wellness, a supplier of CBD ingredients, will initially supply up to 4,200 kg of cannabis ingredients annually

EXMceuticals Inc (CSE:EXM) said it has secured a supply agreement-in-principle of pharmaceutical and medical grade cannabis ingredients totalling a minimum of 8,400 litres of extracts in 2021.

The refined cannabis ingredients maker said the agreements will ensure access to GMP-compliant pharmaceutical and medical grade cannabis for its planned Portugal-based refinery, adding that it has also signed an outline letter of intent (LOI) with one counterparty for the offtake of the eventual supply of finished ingredients.

READ: EXMceuticals secures $2.3M in financing as cannabis producer responds to coronavirus pandemic

EXMceuticals also said that Farmceutica Wellness, a supplier of medical grade cannabidiol (CBD) ingredients, will initially supply up to 4,200 kilograms (kg) of pharmaceutical grade cannabis ingredients to it annually.

The firm intends to purchase up to 9,400 kg annually after the refinery is fully equipped, while a separate LOI is under negotiation for bulk THC importation.

Farmceutica has also signed an outline LOI that will give it the ability to distribute refined cannabinoids manufactured in the refinery, with a focus on the active pharmaceutical ingredients.

EXMceuticals said these agreements will provide sufficient input material to begin operations at its facility as soon as it becomes operational, which assuming funding is received is expected to be the first quarter of 2021.

The refinery will turn raw material and extract into pure finished ingredient products including distillates, isolates and active pharmaceuticals ingredients which will initially be sold on a B2B basis.

Once revenues are achieved EXMceuticals will then seek to enhance revenues by creating final customer products that have been formulated in the existing research and development laboratory in Lisbon.

The company also said that it is in discussions with other emerging producers of GMP compliant cannabis in Portugal, and around the world, that will produce extract to the highest quality standards, saying its position in the middle of the supply chain, will hopefully allow it to emerge as the largest contract manufacturer for the European medical market.

In a statement, EXMceuticals chief executive, Jonathan Summers, said: "These outline supply arrangements are an important step for EXM, as we continue to establish our business model. Securing high-quality source materials from stable sources is a key component, and we have faith these groups will be meaningful partners of ours.

"EXM is now focused on industrial purification, refining and extraction, coupled with a meaningful R&D operation. We aim to be a trusted European source of high-quality cannabis products for the growing demand of the pharmaceuticals and medical Industries. We are eager to work closely with Farmceutica and to provide consistent product to our future clients.”

Contact the author of this article at [email protected]

Quick facts: EXMceuticals

Price: 0.34 CAD

CSE:EXM
Market: CSE
Market Cap: $13.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

EXMceuticals announced LOI with Plena Global to provide THC Distillate in...

EXMceuticals Inc (CSE: EXM) CEO Jonathan Summers joined Steve Darling from Proactive Vancouver to discuss the company signing a Letter of Intent to purchase up to 200 kg of GMP compliment THC Distillate from Plena Global for use in their Portugal facility. Summers telling Proactive about this...

4 weeks, 1 day ago

3 min read